Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 91 | 2025 | 21207 | 4.880 |
Why?
|
Medicare | 78 | 2024 | 6809 | 4.570 |
Why?
|
Medicare Part D | 15 | 2025 | 355 | 4.050 |
Why?
|
Health Expenditures | 25 | 2023 | 2389 | 3.820 |
Why?
|
Colorectal Neoplasms | 53 | 2023 | 6975 | 3.680 |
Why?
|
Medical Oncology | 31 | 2024 | 2346 | 3.590 |
Why?
|
Neoplasms | 71 | 2024 | 22371 | 3.300 |
Why?
|
Hospice Care | 20 | 2022 | 678 | 3.300 |
Why?
|
Lung Neoplasms | 56 | 2023 | 13586 | 2.990 |
Why?
|
SEER Program | 42 | 2024 | 1444 | 2.810 |
Why?
|
Terminal Care | 21 | 2024 | 1770 | 2.810 |
Why?
|
Androgen Antagonists | 23 | 2022 | 1412 | 2.710 |
Why?
|
Mammography | 20 | 2024 | 2433 | 2.680 |
Why?
|
Prostatic Neoplasms | 46 | 2022 | 11101 | 2.500 |
Why?
|
Fee-for-Service Plans | 16 | 2023 | 713 | 2.480 |
Why?
|
United States | 185 | 2025 | 73039 | 2.470 |
Why?
|
Patient Preference | 10 | 2022 | 946 | 2.350 |
Why?
|
Quality of Health Care | 29 | 2022 | 4310 | 2.310 |
Why?
|
Gonadotropin-Releasing Hormone | 17 | 2017 | 1149 | 2.230 |
Why?
|
Insurance Coverage | 21 | 2022 | 1946 | 2.010 |
Why?
|
Antineoplastic Agents | 30 | 2023 | 13677 | 2.000 |
Why?
|
Hospitals, Veterans | 8 | 2015 | 395 | 2.000 |
Why?
|
United States Department of Veterans Affairs | 10 | 2015 | 937 | 1.970 |
Why?
|
Prescription Fees | 4 | 2020 | 153 | 1.860 |
Why?
|
Patient Participation | 14 | 2020 | 1447 | 1.860 |
Why?
|
Aged | 211 | 2025 | 171502 | 1.810 |
Why?
|
Early Detection of Cancer | 19 | 2024 | 3239 | 1.780 |
Why?
|
Cost Sharing | 8 | 2023 | 409 | 1.770 |
Why?
|
Decision Making | 24 | 2020 | 3953 | 1.770 |
Why?
|
Physicians, Primary Care | 8 | 2021 | 624 | 1.750 |
Why?
|
Antineoplastic Agents, Hormonal | 13 | 2017 | 1536 | 1.720 |
Why?
|
Hospices | 11 | 2022 | 245 | 1.700 |
Why?
|
Proxy | 5 | 2020 | 150 | 1.610 |
Why?
|
Physician-Patient Relations | 23 | 2023 | 3269 | 1.600 |
Why?
|
Orchiectomy | 9 | 2014 | 466 | 1.590 |
Why?
|
Physicians | 25 | 2024 | 4598 | 1.590 |
Why?
|
Terminally Ill | 6 | 2016 | 240 | 1.580 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 | 2022 | 686 | 1.580 |
Why?
|
Quality Indicators, Health Care | 13 | 2021 | 1805 | 1.550 |
Why?
|
Aged, 80 and over | 108 | 2024 | 59626 | 1.360 |
Why?
|
Humans | 355 | 2025 | 768171 | 1.360 |
Why?
|
Prescription Drugs | 8 | 2023 | 635 | 1.350 |
Why?
|
Insurance, Health | 14 | 2022 | 2517 | 1.350 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 12 | 2023 | 5432 | 1.340 |
Why?
|
Specialization | 9 | 2023 | 779 | 1.300 |
Why?
|
Neoplasm Staging | 39 | 2025 | 11244 | 1.290 |
Why?
|
Female | 223 | 2025 | 397187 | 1.250 |
Why?
|
Medicare Part C | 2 | 2024 | 332 | 1.230 |
Why?
|
Referral and Consultation | 20 | 2021 | 3620 | 1.220 |
Why?
|
Reimbursement Mechanisms | 4 | 2023 | 670 | 1.200 |
Why?
|
Contraceptive Agents, Female | 3 | 2019 | 123 | 1.190 |
Why?
|
Healthcare Disparities | 13 | 2022 | 3415 | 1.190 |
Why?
|
Insurance, Pharmaceutical Services | 7 | 2021 | 348 | 1.150 |
Why?
|
Choice Behavior | 7 | 2016 | 848 | 1.130 |
Why?
|
Patient Protection and Affordable Care Act | 8 | 2021 | 1188 | 1.120 |
Why?
|
Drug Costs | 11 | 2023 | 1195 | 1.100 |
Why?
|
Survivors | 15 | 2023 | 2381 | 1.070 |
Why?
|
Middle Aged | 149 | 2025 | 223487 | 1.060 |
Why?
|
Insurance, Health, Reimbursement | 4 | 2015 | 388 | 1.020 |
Why?
|
Male | 171 | 2025 | 364731 | 1.010 |
Why?
|
Chemotherapy, Adjuvant | 16 | 2021 | 3556 | 1.000 |
Why?
|
Pharmacies | 2 | 2025 | 171 | 0.980 |
Why?
|
Neoplasms, Hormone-Dependent | 4 | 2014 | 410 | 0.970 |
Why?
|
Health Knowledge, Attitudes, Practice | 9 | 2018 | 4055 | 0.950 |
Why?
|
Medicaid | 10 | 2022 | 2840 | 0.940 |
Why?
|
Cancer Care Facilities | 6 | 2025 | 427 | 0.940 |
Why?
|
Interdisciplinary Communication | 5 | 2015 | 937 | 0.910 |
Why?
|
Insurance Benefits | 3 | 2019 | 185 | 0.900 |
Why?
|
Health Care Surveys | 16 | 2023 | 2434 | 0.890 |
Why?
|
Health Care Costs | 10 | 2023 | 3239 | 0.880 |
Why?
|
Insurance Claim Review | 8 | 2022 | 744 | 0.870 |
Why?
|
Logistic Models | 34 | 2020 | 13290 | 0.860 |
Why?
|
Prostatectomy | 10 | 2022 | 1786 | 0.850 |
Why?
|
Drugs, Generic | 7 | 2023 | 455 | 0.840 |
Why?
|
Primary Health Care | 14 | 2021 | 4746 | 0.830 |
Why?
|
Attitude of Health Personnel | 11 | 2021 | 3929 | 0.820 |
Why?
|
Peer Group | 2 | 2019 | 700 | 0.820 |
Why?
|
Medication Adherence | 9 | 2023 | 2187 | 0.800 |
Why?
|
Mastectomy, Segmental | 7 | 2022 | 974 | 0.800 |
Why?
|
Patient Satisfaction | 13 | 2018 | 3490 | 0.800 |
Why?
|
Intrauterine Devices | 3 | 2019 | 115 | 0.790 |
Why?
|
Veterans | 8 | 2022 | 2669 | 0.750 |
Why?
|
Cohort Studies | 52 | 2023 | 41753 | 0.750 |
Why?
|
Diabetes Mellitus | 13 | 2019 | 5891 | 0.740 |
Why?
|
Health Services Accessibility | 13 | 2025 | 5520 | 0.720 |
Why?
|
Health Status Disparities | 3 | 2022 | 1885 | 0.710 |
Why?
|
Hospitals | 7 | 2016 | 3886 | 0.700 |
Why?
|
Formularies as Topic | 3 | 2019 | 94 | 0.670 |
Why?
|
Family | 6 | 2017 | 3209 | 0.670 |
Why?
|
Mass Screening | 12 | 2024 | 5458 | 0.660 |
Why?
|
Drug Prescriptions | 8 | 2022 | 1668 | 0.660 |
Why?
|
Patient Care Team | 5 | 2015 | 2523 | 0.660 |
Why?
|
Managed Care Programs | 4 | 2006 | 939 | 0.650 |
Why?
|
Communication | 12 | 2022 | 3905 | 0.650 |
Why?
|
Prescriptions | 3 | 2023 | 388 | 0.640 |
Why?
|
Adult | 96 | 2025 | 223646 | 0.640 |
Why?
|
Continuity of Patient Care | 6 | 2022 | 1078 | 0.630 |
Why?
|
Legislation, Medical | 1 | 2019 | 99 | 0.630 |
Why?
|
Income | 5 | 2021 | 1878 | 0.620 |
Why?
|
Geography | 2 | 2018 | 652 | 0.620 |
Why?
|
Neoplasms, Glandular and Epithelial | 3 | 2018 | 489 | 0.610 |
Why?
|
Delivery of Health Care | 10 | 2023 | 5367 | 0.610 |
Why?
|
Home Care Services | 4 | 2013 | 659 | 0.610 |
Why?
|
Medically Uninsured | 4 | 2020 | 840 | 0.610 |
Why?
|
Ovarian Neoplasms | 8 | 2022 | 4916 | 0.600 |
Why?
|
Breast | 5 | 2023 | 1976 | 0.590 |
Why?
|
Administration, Oral | 8 | 2020 | 4034 | 0.580 |
Why?
|
Life Expectancy | 7 | 2022 | 1248 | 0.570 |
Why?
|
Ambulatory Care | 5 | 2015 | 2783 | 0.560 |
Why?
|
Mastectomy | 8 | 2016 | 1862 | 0.560 |
Why?
|
Contraception Behavior | 1 | 2019 | 186 | 0.560 |
Why?
|
Mouth Neoplasms | 1 | 2022 | 597 | 0.550 |
Why?
|
Minority Health | 2 | 2015 | 79 | 0.540 |
Why?
|
Patient Care Planning | 2 | 2020 | 905 | 0.540 |
Why?
|
Health Services Research | 9 | 2019 | 1815 | 0.540 |
Why?
|
Odds Ratio | 13 | 2020 | 9669 | 0.530 |
Why?
|
Interprofessional Relations | 7 | 2017 | 997 | 0.530 |
Why?
|
Aromatase Inhibitors | 4 | 2013 | 519 | 0.530 |
Why?
|
Practice Guidelines as Topic | 14 | 2024 | 7454 | 0.520 |
Why?
|
Cross-Sectional Studies | 27 | 2025 | 26379 | 0.510 |
Why?
|
Kidney Failure, Chronic | 5 | 2022 | 2496 | 0.510 |
Why?
|
Peer Review, Research | 1 | 2019 | 344 | 0.510 |
Why?
|
Combined Modality Therapy | 6 | 2019 | 8542 | 0.510 |
Why?
|
Employment | 4 | 2010 | 1110 | 0.510 |
Why?
|
Government Regulation | 2 | 2019 | 525 | 0.510 |
Why?
|
Emigrants and Immigrants | 3 | 2013 | 550 | 0.500 |
Why?
|
California | 8 | 2017 | 1438 | 0.500 |
Why?
|
Communicable Diseases | 1 | 2024 | 873 | 0.500 |
Why?
|
Socioeconomic Factors | 15 | 2018 | 7852 | 0.490 |
Why?
|
Patient Care | 4 | 2019 | 629 | 0.490 |
Why?
|
Diabetes Complications | 3 | 2018 | 1320 | 0.490 |
Why?
|
Leukemia | 1 | 2023 | 1519 | 0.490 |
Why?
|
Reimbursement, Incentive | 3 | 2014 | 541 | 0.480 |
Why?
|
False Positive Reactions | 4 | 2019 | 963 | 0.480 |
Why?
|
Proportional Hazards Models | 17 | 2022 | 12543 | 0.470 |
Why?
|
Propensity Score | 9 | 2018 | 1969 | 0.470 |
Why?
|
Health Literacy | 2 | 2023 | 466 | 0.460 |
Why?
|
Research Personnel | 2 | 2019 | 589 | 0.460 |
Why?
|
Preferred Provider Organizations | 2 | 2019 | 37 | 0.460 |
Why?
|
Nursing Homes | 4 | 2010 | 1084 | 0.460 |
Why?
|
Angiogenesis Inhibitors | 2 | 2015 | 2057 | 0.450 |
Why?
|
Age Factors | 22 | 2018 | 18415 | 0.450 |
Why?
|
Medicare Part B | 2 | 2022 | 116 | 0.440 |
Why?
|
Benzamides | 2 | 2022 | 1379 | 0.430 |
Why?
|
Disclosure | 1 | 2019 | 755 | 0.430 |
Why?
|
Calcifediol | 1 | 2014 | 160 | 0.430 |
Why?
|
Neoadjuvant Therapy | 5 | 2021 | 2907 | 0.420 |
Why?
|
Ownership | 3 | 2025 | 338 | 0.420 |
Why?
|
Cardiovascular Diseases | 14 | 2017 | 15662 | 0.420 |
Why?
|
Colonic Neoplasms | 4 | 2015 | 2541 | 0.420 |
Why?
|
Contraception | 1 | 2016 | 362 | 0.420 |
Why?
|
Health Services Misuse | 1 | 2014 | 246 | 0.410 |
Why?
|
Bile Duct Diseases | 1 | 2013 | 98 | 0.410 |
Why?
|
Radiotherapy, Adjuvant | 10 | 2016 | 1791 | 0.400 |
Why?
|
Rwanda | 8 | 2025 | 671 | 0.400 |
Why?
|
Practice Management, Medical | 3 | 2019 | 191 | 0.400 |
Why?
|
Politics | 1 | 2019 | 822 | 0.390 |
Why?
|
Caregivers | 4 | 2022 | 2302 | 0.380 |
Why?
|
Multivariate Analysis | 15 | 2017 | 12077 | 0.380 |
Why?
|
Guideline Adherence | 8 | 2015 | 2235 | 0.370 |
Why?
|
Pulmonary Surgical Procedures | 1 | 2011 | 33 | 0.370 |
Why?
|
Physician Incentive Plans | 1 | 2012 | 165 | 0.370 |
Why?
|
Catastrophization | 1 | 2015 | 352 | 0.370 |
Why?
|
Patient Acceptance of Health Care | 4 | 2018 | 3231 | 0.370 |
Why?
|
Tamoxifen | 2 | 2012 | 966 | 0.370 |
Why?
|
Data Collection | 10 | 2015 | 3326 | 0.370 |
Why?
|
Health Facility Size | 2 | 2012 | 59 | 0.360 |
Why?
|
Neoplasm Metastasis | 11 | 2018 | 4913 | 0.360 |
Why?
|
Medical Records | 2 | 2015 | 1410 | 0.360 |
Why?
|
Trust | 2 | 2007 | 532 | 0.360 |
Why?
|
BRCA2 Protein | 2 | 2022 | 802 | 0.360 |
Why?
|
Radiotherapy | 3 | 2015 | 1502 | 0.360 |
Why?
|
Aftercare | 1 | 2017 | 916 | 0.360 |
Why?
|
Truth Disclosure | 2 | 2014 | 434 | 0.350 |
Why?
|
Hospital Costs | 3 | 2018 | 957 | 0.350 |
Why?
|
Colonoscopy | 3 | 2018 | 1409 | 0.350 |
Why?
|
Thiazides | 1 | 2010 | 19 | 0.350 |
Why?
|
Motivation | 1 | 2020 | 2020 | 0.350 |
Why?
|
Diphenhydramine | 1 | 2010 | 63 | 0.350 |
Why?
|
Medicine | 5 | 2011 | 945 | 0.340 |
Why?
|
Sodium Chloride Symporter Inhibitors | 1 | 2010 | 78 | 0.340 |
Why?
|
Bone Density | 3 | 2012 | 3573 | 0.340 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2015 | 454 | 0.340 |
Why?
|
Myocardial Infarction | 8 | 2014 | 11519 | 0.340 |
Why?
|
Health Status | 6 | 2020 | 4091 | 0.340 |
Why?
|
Models, Theoretical | 2 | 2019 | 3573 | 0.330 |
Why?
|
Uterine Cervical Neoplasms | 3 | 2023 | 2043 | 0.330 |
Why?
|
Quality of Life | 10 | 2022 | 13490 | 0.330 |
Why?
|
Time Factors | 20 | 2021 | 40220 | 0.330 |
Why?
|
Bone Neoplasms | 1 | 2022 | 2565 | 0.330 |
Why?
|
Palliative Care | 8 | 2019 | 3643 | 0.330 |
Why?
|
Risk Factors | 27 | 2021 | 74944 | 0.320 |
Why?
|
Delivery of Health Care, Integrated | 4 | 2023 | 951 | 0.320 |
Why?
|
Protein-Tyrosine Kinases | 3 | 2017 | 2433 | 0.320 |
Why?
|
BRCA1 Protein | 2 | 2022 | 1155 | 0.320 |
Why?
|
Social Support | 2 | 2011 | 2193 | 0.320 |
Why?
|
Cost of Illness | 3 | 2022 | 1951 | 0.320 |
Why?
|
Insurance Carriers | 3 | 2025 | 159 | 0.320 |
Why?
|
Patient Selection | 4 | 2014 | 4260 | 0.320 |
Why?
|
Ibuprofen | 1 | 2010 | 229 | 0.310 |
Why?
|
Length of Stay | 5 | 2018 | 6498 | 0.310 |
Why?
|
Comorbidity | 11 | 2015 | 10590 | 0.310 |
Why?
|
Health Education | 1 | 2015 | 1059 | 0.300 |
Why?
|
Ultraviolet Rays | 1 | 2013 | 1103 | 0.300 |
Why?
|
Retrospective Studies | 37 | 2025 | 81760 | 0.300 |
Why?
|
Prospective Studies | 21 | 2021 | 54924 | 0.300 |
Why?
|
Registries | 10 | 2022 | 8375 | 0.300 |
Why?
|
Young Adult | 24 | 2019 | 60066 | 0.290 |
Why?
|
Health Facilities | 3 | 2019 | 577 | 0.290 |
Why?
|
Risk | 6 | 2019 | 9613 | 0.290 |
Why?
|
Commerce | 3 | 2023 | 612 | 0.280 |
Why?
|
Ultrasonography, Mammary | 2 | 2019 | 243 | 0.280 |
Why?
|
Comprehension | 3 | 2019 | 638 | 0.280 |
Why?
|
Survival Rate | 13 | 2019 | 12840 | 0.270 |
Why?
|
Maryland | 3 | 2023 | 278 | 0.270 |
Why?
|
Patient Transfer | 2 | 2011 | 792 | 0.270 |
Why?
|
National Cancer Institute (U.S.) | 3 | 2023 | 300 | 0.270 |
Why?
|
Pneumonectomy | 2 | 2011 | 1156 | 0.260 |
Why?
|
Patient-Centered Care | 2 | 2017 | 1444 | 0.260 |
Why?
|
Prognosis | 12 | 2023 | 30009 | 0.260 |
Why?
|
Minnesota | 5 | 2004 | 339 | 0.260 |
Why?
|
Cost Savings | 2 | 2021 | 904 | 0.260 |
Why?
|
Treatment Outcome | 21 | 2022 | 65379 | 0.250 |
Why?
|
Insulin | 1 | 2020 | 6610 | 0.250 |
Why?
|
Health Care Reform | 3 | 2020 | 1256 | 0.250 |
Why?
|
Health Promotion | 2 | 2014 | 2210 | 0.250 |
Why?
|
Health Personnel | 3 | 2019 | 3384 | 0.250 |
Why?
|
Costs and Cost Analysis | 4 | 2022 | 1667 | 0.240 |
Why?
|
Mammaplasty | 1 | 2015 | 1269 | 0.240 |
Why?
|
Radiation Oncology | 3 | 2015 | 572 | 0.240 |
Why?
|
Community Networks | 3 | 2018 | 202 | 0.240 |
Why?
|
Quality Improvement | 2 | 2019 | 3857 | 0.240 |
Why?
|
Population Surveillance | 5 | 2017 | 2596 | 0.240 |
Why?
|
Cost Control | 3 | 2019 | 627 | 0.230 |
Why?
|
Community Health Services | 2 | 2009 | 659 | 0.230 |
Why?
|
Residence Characteristics | 5 | 2016 | 2118 | 0.230 |
Why?
|
Vitamin D Deficiency | 1 | 2014 | 1388 | 0.230 |
Why?
|
Hospitalization | 9 | 2021 | 10840 | 0.230 |
Why?
|
Military Personnel | 1 | 2013 | 1261 | 0.230 |
Why?
|
Incidence | 11 | 2016 | 21538 | 0.230 |
Why?
|
Interviews as Topic | 5 | 2019 | 2741 | 0.230 |
Why?
|
Activities of Daily Living | 3 | 2008 | 2430 | 0.220 |
Why?
|
Workload | 1 | 2009 | 849 | 0.220 |
Why?
|
Receptor, erbB-2 | 4 | 2016 | 2603 | 0.220 |
Why?
|
Triazoles | 1 | 2009 | 904 | 0.220 |
Why?
|
Unnecessary Procedures | 1 | 2007 | 412 | 0.220 |
Why?
|
Health Benefit Plans, Employee | 2 | 2018 | 332 | 0.210 |
Why?
|
Smoking | 5 | 2014 | 9092 | 0.210 |
Why?
|
Genetic Testing | 3 | 2022 | 3591 | 0.210 |
Why?
|
Fees, Pharmaceutical | 2 | 2020 | 66 | 0.210 |
Why?
|
Eligibility Determination | 1 | 2007 | 421 | 0.210 |
Why?
|
Pyrazines | 1 | 2009 | 1205 | 0.210 |
Why?
|
Goals | 3 | 2023 | 717 | 0.210 |
Why?
|
Evidence-Based Medicine | 6 | 2014 | 3706 | 0.210 |
Why?
|
Minority Groups | 3 | 2016 | 1216 | 0.210 |
Why?
|
Piperazines | 1 | 2013 | 2554 | 0.210 |
Why?
|
Multiple Myeloma | 2 | 2020 | 5196 | 0.210 |
Why?
|
Protein Kinase Inhibitors | 3 | 2020 | 5704 | 0.210 |
Why?
|
Health Behavior | 3 | 2011 | 2650 | 0.210 |
Why?
|
Drug Utilization | 3 | 2021 | 1189 | 0.210 |
Why?
|
Diabetes Mellitus, Type 2 | 5 | 2012 | 12252 | 0.210 |
Why?
|
Sensitivity and Specificity | 6 | 2019 | 14729 | 0.200 |
Why?
|
Medicare Part A | 1 | 2022 | 40 | 0.200 |
Why?
|
Survival Analysis | 8 | 2018 | 10099 | 0.200 |
Why?
|
Emetics | 1 | 2022 | 9 | 0.200 |
Why?
|
Severity of Illness Index | 5 | 2017 | 15949 | 0.200 |
Why?
|
Periodicals as Topic | 2 | 2023 | 1465 | 0.200 |
Why?
|
Diabetic Angiopathies | 1 | 2007 | 806 | 0.200 |
Why?
|
Therapies, Investigational | 1 | 2023 | 111 | 0.200 |
Why?
|
Rosa | 1 | 2021 | 8 | 0.200 |
Why?
|
United States Food and Drug Administration | 3 | 2019 | 1673 | 0.200 |
Why?
|
Chi-Square Distribution | 6 | 2018 | 3436 | 0.190 |
Why?
|
Sunlight | 2 | 2014 | 337 | 0.190 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2022 | 9419 | 0.190 |
Why?
|
Regression Analysis | 6 | 2017 | 6340 | 0.190 |
Why?
|
Longevity | 2 | 2015 | 1077 | 0.190 |
Why?
|
Pyrimidines | 1 | 2013 | 3048 | 0.190 |
Why?
|
Psychotropic Drugs | 1 | 2007 | 881 | 0.190 |
Why?
|
Stroke | 4 | 2014 | 9755 | 0.190 |
Why?
|
Family Practice | 1 | 2004 | 509 | 0.190 |
Why?
|
Rural Population | 3 | 2025 | 2325 | 0.190 |
Why?
|
Perception | 2 | 2020 | 1209 | 0.190 |
Why?
|
Metformin | 1 | 2009 | 909 | 0.190 |
Why?
|
Diagnostic Tests, Routine | 1 | 2007 | 789 | 0.180 |
Why?
|
Drug Therapy | 2 | 2015 | 504 | 0.180 |
Why?
|
Episode of Care | 1 | 2021 | 127 | 0.180 |
Why?
|
Androstenes | 1 | 2022 | 177 | 0.180 |
Why?
|
Longitudinal Studies | 6 | 2018 | 14783 | 0.180 |
Why?
|
Long-Term Care | 2 | 2020 | 631 | 0.180 |
Why?
|
Genomics | 1 | 2017 | 5926 | 0.180 |
Why?
|
Phenylthiohydantoin | 1 | 2022 | 207 | 0.180 |
Why?
|
Deductibles and Coinsurance | 2 | 2021 | 315 | 0.180 |
Why?
|
Advance Directives | 2 | 2020 | 249 | 0.180 |
Why?
|
Turner Syndrome | 1 | 2022 | 130 | 0.180 |
Why?
|
Hypoglycemic Agents | 3 | 2019 | 3109 | 0.180 |
Why?
|
Diagnostic Imaging | 1 | 2014 | 3533 | 0.180 |
Why?
|
Budgets | 1 | 2022 | 232 | 0.180 |
Why?
|
Antidepressive Agents | 1 | 2012 | 2913 | 0.180 |
Why?
|
Biopsy | 4 | 2019 | 6792 | 0.180 |
Why?
|
Peripheral Arterial Disease | 1 | 2012 | 1304 | 0.170 |
Why?
|
Postal Service | 1 | 2020 | 96 | 0.170 |
Why?
|
General Surgery | 3 | 2023 | 1720 | 0.170 |
Why?
|
Fasting | 1 | 2006 | 1610 | 0.170 |
Why?
|
Fractures, Bone | 2 | 2011 | 2062 | 0.170 |
Why?
|
Philadelphia | 1 | 2020 | 271 | 0.170 |
Why?
|
Massachusetts | 5 | 2022 | 8890 | 0.170 |
Why?
|
Salvage Therapy | 2 | 2016 | 1273 | 0.170 |
Why?
|
Intensive Care Units | 5 | 2020 | 3800 | 0.170 |
Why?
|
Internal Medicine | 2 | 2013 | 1064 | 0.170 |
Why?
|
Teaching | 2 | 2019 | 1171 | 0.170 |
Why?
|
Nitriles | 2 | 2022 | 980 | 0.160 |
Why?
|
Vitamin D | 1 | 2013 | 3311 | 0.160 |
Why?
|
Sick Leave | 1 | 1999 | 105 | 0.160 |
Why?
|
Research Design | 5 | 2012 | 6209 | 0.160 |
Why?
|
For-Profit Insurance Plans | 1 | 2018 | 8 | 0.160 |
Why?
|
Testosterone | 1 | 2009 | 2491 | 0.160 |
Why?
|
Travel | 1 | 2025 | 805 | 0.160 |
Why?
|
Blood Glucose | 3 | 2010 | 6431 | 0.160 |
Why?
|
Venous Thromboembolism | 1 | 2012 | 1882 | 0.150 |
Why?
|
Information Dissemination | 1 | 2007 | 1143 | 0.150 |
Why?
|
Health Services for the Aged | 1 | 2021 | 264 | 0.150 |
Why?
|
Disease-Free Survival | 3 | 2018 | 6847 | 0.150 |
Why?
|
Models, Economic | 2 | 2019 | 719 | 0.150 |
Why?
|
Drug Implants | 1 | 2019 | 230 | 0.150 |
Why?
|
Follow-Up Studies | 9 | 2022 | 39354 | 0.150 |
Why?
|
Negotiating | 2 | 2023 | 152 | 0.150 |
Why?
|
Professional Practice | 3 | 2012 | 314 | 0.150 |
Why?
|
Clinical Trials as Topic | 5 | 2019 | 8052 | 0.150 |
Why?
|
Residential Facilities | 1 | 2018 | 41 | 0.150 |
Why?
|
Cooperative Behavior | 3 | 2015 | 1514 | 0.150 |
Why?
|
Health Policy | 3 | 2019 | 2697 | 0.150 |
Why?
|
Role | 3 | 2010 | 176 | 0.140 |
Why?
|
Reproductive Techniques, Assisted | 1 | 2022 | 504 | 0.140 |
Why?
|
Africa South of the Sahara | 1 | 2020 | 752 | 0.140 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 2 | 2010 | 3252 | 0.140 |
Why?
|
Tennessee | 1 | 2017 | 123 | 0.140 |
Why?
|
Personnel, Hospital | 1 | 1999 | 285 | 0.140 |
Why?
|
Death, Sudden, Cardiac | 3 | 2012 | 1567 | 0.140 |
Why?
|
Patients | 4 | 2017 | 908 | 0.140 |
Why?
|
Quality Assurance, Health Care | 1 | 2007 | 2176 | 0.140 |
Why?
|
Women's Health | 1 | 2007 | 2082 | 0.140 |
Why?
|
Private Sector | 2 | 2011 | 396 | 0.140 |
Why?
|
Liver Neoplasms | 1 | 2013 | 4363 | 0.140 |
Why?
|
Death | 5 | 2023 | 683 | 0.140 |
Why?
|
Clinical Competence | 4 | 2018 | 4858 | 0.140 |
Why?
|
Area Under Curve | 2 | 2019 | 1643 | 0.140 |
Why?
|
Adolescent | 11 | 2019 | 89169 | 0.140 |
Why?
|
Hysterectomy | 2 | 2018 | 863 | 0.130 |
Why?
|
Patient Education as Topic | 4 | 2014 | 2337 | 0.130 |
Why?
|
Risk Assessment | 11 | 2016 | 24318 | 0.130 |
Why?
|
Job Satisfaction | 2 | 2014 | 548 | 0.130 |
Why?
|
Infusions, Intravenous | 2 | 2018 | 2230 | 0.130 |
Why?
|
Attitude to Health | 2 | 2017 | 2025 | 0.130 |
Why?
|
Delayed Diagnosis | 2 | 2022 | 467 | 0.130 |
Why?
|
Kaplan-Meier Estimate | 5 | 2018 | 6525 | 0.130 |
Why?
|
Analgesics, Opioid | 2 | 2023 | 3837 | 0.130 |
Why?
|
Family Health | 1 | 2020 | 1255 | 0.130 |
Why?
|
Mental Health | 4 | 2018 | 3275 | 0.130 |
Why?
|
Aspirin | 1 | 2007 | 3135 | 0.120 |
Why?
|
Prostate-Specific Antigen | 5 | 2018 | 2463 | 0.120 |
Why?
|
Intestinal Perforation | 1 | 2017 | 254 | 0.120 |
Why?
|
Contract Services | 1 | 2015 | 90 | 0.120 |
Why?
|
Subacute Care | 1 | 2018 | 187 | 0.120 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2007 | 2763 | 0.120 |
Why?
|
Goserelin | 2 | 2017 | 126 | 0.120 |
Why?
|
Educational Status | 2 | 2013 | 2515 | 0.120 |
Why?
|
Colitis, Ulcerative | 1 | 2007 | 1926 | 0.120 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2016 | 218 | 0.120 |
Why?
|
Postmenopause | 3 | 2013 | 2518 | 0.120 |
Why?
|
Research | 2 | 2022 | 1979 | 0.120 |
Why?
|
Iowa | 1 | 2014 | 100 | 0.120 |
Why?
|
Culture | 1 | 2018 | 622 | 0.110 |
Why?
|
Sleep | 1 | 2010 | 4818 | 0.110 |
Why?
|
Databases, Factual | 4 | 2018 | 8080 | 0.110 |
Why?
|
Withholding Treatment | 2 | 2016 | 620 | 0.110 |
Why?
|
Alabama | 1 | 2014 | 112 | 0.110 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 195 | 0.110 |
Why?
|
Fees and Charges | 1 | 2015 | 189 | 0.110 |
Why?
|
Leuprolide | 2 | 2017 | 313 | 0.110 |
Why?
|
Needs Assessment | 2 | 2017 | 1141 | 0.110 |
Why?
|
Carcinoma, Endometrioid | 1 | 2016 | 275 | 0.110 |
Why?
|
Hospitals, Rural | 1 | 2015 | 174 | 0.110 |
Why?
|
Algorithms | 4 | 2021 | 14164 | 0.110 |
Why?
|
North Carolina | 1 | 2014 | 329 | 0.110 |
Why?
|
Heart Diseases | 1 | 2006 | 2819 | 0.110 |
Why?
|
Genital Neoplasms, Female | 1 | 2018 | 536 | 0.110 |
Why?
|
Hormone Replacement Therapy | 1 | 1999 | 757 | 0.110 |
Why?
|
Information Seeking Behavior | 1 | 2014 | 116 | 0.110 |
Why?
|
Lymph Node Excision | 3 | 2016 | 1271 | 0.110 |
Why?
|
Physician's Role | 2 | 2011 | 925 | 0.110 |
Why?
|
Cost-Benefit Analysis | 4 | 2016 | 5536 | 0.110 |
Why?
|
Risk Reduction Behavior | 1 | 2019 | 1119 | 0.100 |
Why?
|
Poverty | 2 | 2022 | 2720 | 0.100 |
Why?
|
Thalidomide | 1 | 2018 | 886 | 0.100 |
Why?
|
Life Tables | 1 | 2013 | 367 | 0.100 |
Why?
|
Endpoint Determination | 1 | 2015 | 592 | 0.100 |
Why?
|
Veterans Health | 1 | 2014 | 216 | 0.100 |
Why?
|
Seasons | 2 | 2014 | 1524 | 0.100 |
Why?
|
Ultrasonography | 2 | 2016 | 6004 | 0.100 |
Why?
|
Confidence Intervals | 2 | 2012 | 2923 | 0.100 |
Why?
|
Health Services | 1 | 2017 | 755 | 0.100 |
Why?
|
Professional-Family Relations | 1 | 2016 | 501 | 0.100 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2017 | 1126 | 0.100 |
Why?
|
Review Literature as Topic | 1 | 2014 | 297 | 0.100 |
Why?
|
Drug Industry | 2 | 2019 | 791 | 0.100 |
Why?
|
Hospital-Physician Joint Ventures | 1 | 2012 | 30 | 0.100 |
Why?
|
Mexico | 1 | 2014 | 769 | 0.100 |
Why?
|
Awareness | 2 | 2014 | 653 | 0.100 |
Why?
|
Factor Analysis, Statistical | 1 | 2015 | 1001 | 0.100 |
Why?
|
Carcinoma, Lobular | 1 | 2016 | 480 | 0.100 |
Why?
|
Reproducibility of Results | 2 | 2021 | 20225 | 0.100 |
Why?
|
Statistics, Nonparametric | 3 | 2004 | 2862 | 0.100 |
Why?
|
Pilot Projects | 2 | 2022 | 8741 | 0.090 |
Why?
|
Academic Medical Centers | 3 | 2013 | 2785 | 0.090 |
Why?
|
Orthopedics | 1 | 2000 | 906 | 0.090 |
Why?
|
Medical Record Linkage | 1 | 2012 | 286 | 0.090 |
Why?
|
Immunologic Factors | 1 | 2020 | 1596 | 0.090 |
Why?
|
Geriatric Assessment | 2 | 2021 | 1422 | 0.090 |
Why?
|
Behavioral Risk Factor Surveillance System | 1 | 2012 | 211 | 0.090 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2016 | 620 | 0.090 |
Why?
|
Pain | 2 | 2017 | 5099 | 0.090 |
Why?
|
Organizational Affiliation | 1 | 2010 | 34 | 0.090 |
Why?
|
Natural Language Processing | 1 | 2020 | 1203 | 0.090 |
Why?
|
Patient Readmission | 2 | 2022 | 3288 | 0.090 |
Why?
|
Preoperative Care | 1 | 2019 | 2258 | 0.090 |
Why?
|
Drug Labeling | 1 | 2012 | 250 | 0.090 |
Why?
|
Advance Care Planning | 1 | 2017 | 698 | 0.080 |
Why?
|
Receptors, Progesterone | 1 | 2015 | 1160 | 0.080 |
Why?
|
Hypertension | 1 | 2010 | 8616 | 0.080 |
Why?
|
Disease Outbreaks | 1 | 1999 | 1761 | 0.080 |
Why?
|
Patient Compliance | 2 | 2018 | 2697 | 0.080 |
Why?
|
Friends | 1 | 2011 | 149 | 0.080 |
Why?
|
Attitude to Death | 1 | 2012 | 400 | 0.080 |
Why?
|
Pregnancy | 3 | 2022 | 30255 | 0.080 |
Why?
|
Linear Models | 4 | 2018 | 5884 | 0.080 |
Why?
|
Photons | 1 | 2013 | 594 | 0.080 |
Why?
|
Cause of Death | 2 | 2018 | 3721 | 0.080 |
Why?
|
North America | 2 | 2015 | 1289 | 0.080 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2013 | 542 | 0.080 |
Why?
|
Mortality | 1 | 2020 | 2911 | 0.080 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2015 | 11878 | 0.080 |
Why?
|
Meta-Analysis as Topic | 1 | 2014 | 1363 | 0.080 |
Why?
|
Transurethral Resection of Prostate | 1 | 2009 | 77 | 0.080 |
Why?
|
Social Perception | 1 | 2012 | 434 | 0.080 |
Why?
|
Cardiology | 1 | 2000 | 1702 | 0.080 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2016 | 1099 | 0.080 |
Why?
|
Aging | 1 | 2008 | 8743 | 0.080 |
Why?
|
Organizations, Nonprofit | 1 | 2009 | 105 | 0.080 |
Why?
|
Laparoscopy | 2 | 2018 | 2041 | 0.080 |
Why?
|
Age of Onset | 2 | 2015 | 3346 | 0.080 |
Why?
|
Influenza, Human | 1 | 1999 | 1541 | 0.080 |
Why?
|
Small-Area Analysis | 1 | 2008 | 51 | 0.070 |
Why?
|
Disease Management | 1 | 2019 | 2535 | 0.070 |
Why?
|
Drug Approval | 1 | 2015 | 821 | 0.070 |
Why?
|
Drug Interactions | 1 | 2012 | 1419 | 0.070 |
Why?
|
Medical Order Entry Systems | 1 | 2013 | 524 | 0.070 |
Why?
|
Estrogens | 1 | 2014 | 1536 | 0.070 |
Why?
|
Health Surveys | 1 | 2018 | 4057 | 0.070 |
Why?
|
Smoking Cessation | 3 | 2019 | 2085 | 0.070 |
Why?
|
Emotions | 1 | 2019 | 2767 | 0.070 |
Why?
|
Arrhythmias, Cardiac | 1 | 2017 | 2258 | 0.070 |
Why?
|
Public Sector | 1 | 2009 | 266 | 0.070 |
Why?
|
Physicians, Family | 1 | 2009 | 349 | 0.070 |
Why?
|
New England | 1 | 2010 | 1058 | 0.070 |
Why?
|
International Cooperation | 1 | 2014 | 1436 | 0.070 |
Why?
|
Geriatrics | 1 | 2012 | 394 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2015 | 10397 | 0.070 |
Why?
|
Financing, Personal | 1 | 2009 | 310 | 0.070 |
Why?
|
Postoperative Complications | 1 | 2009 | 15833 | 0.070 |
Why?
|
Immunotherapy | 1 | 2023 | 4754 | 0.070 |
Why?
|
Mental Disorders | 1 | 2007 | 6873 | 0.070 |
Why?
|
Institutionalization | 1 | 2007 | 108 | 0.070 |
Why?
|
Forecasting | 1 | 2016 | 2945 | 0.070 |
Why?
|
Lymph Nodes | 2 | 2016 | 3474 | 0.070 |
Why?
|
Life Style | 1 | 2018 | 3932 | 0.070 |
Why?
|
Siblings | 1 | 2011 | 828 | 0.070 |
Why?
|
Hormones | 1 | 2010 | 866 | 0.070 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2010 | 497 | 0.070 |
Why?
|
Receptors, Estrogen | 1 | 2015 | 2253 | 0.070 |
Why?
|
Renal Dialysis | 3 | 2022 | 1791 | 0.070 |
Why?
|
Patient Discharge | 2 | 2010 | 3479 | 0.070 |
Why?
|
Marriage | 2 | 2010 | 351 | 0.070 |
Why?
|
Quality-Adjusted Life Years | 1 | 2013 | 1741 | 0.070 |
Why?
|
Self Report | 2 | 2020 | 3773 | 0.070 |
Why?
|
Specialties, Surgical | 1 | 2011 | 391 | 0.070 |
Why?
|
Erectile Dysfunction | 1 | 2009 | 437 | 0.070 |
Why?
|
Rectal Neoplasms | 2 | 2012 | 1183 | 0.060 |
Why?
|
Uncertainty | 2 | 2022 | 769 | 0.060 |
Why?
|
Empathy | 1 | 2010 | 474 | 0.060 |
Why?
|
Blood Glucose Self-Monitoring | 1 | 2009 | 475 | 0.060 |
Why?
|
Advisory Committees | 1 | 2010 | 796 | 0.060 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2012 | 1657 | 0.060 |
Why?
|
Patient Admission | 1 | 2012 | 1365 | 0.060 |
Why?
|
Coronary Disease | 2 | 2012 | 5919 | 0.060 |
Why?
|
Neoplasms, Second Primary | 1 | 2013 | 1061 | 0.060 |
Why?
|
Urinary Incontinence | 1 | 2009 | 490 | 0.060 |
Why?
|
Depression | 3 | 2014 | 8230 | 0.060 |
Why?
|
Pediatrics | 1 | 2000 | 3629 | 0.060 |
Why?
|
Genetic Counseling | 1 | 2008 | 635 | 0.060 |
Why?
|
Social Class | 2 | 2010 | 2008 | 0.060 |
Why?
|
Early Diagnosis | 1 | 2009 | 1194 | 0.060 |
Why?
|
Health Resources | 1 | 2010 | 950 | 0.060 |
Why?
|
Internet | 1 | 2016 | 3110 | 0.060 |
Why?
|
Drug Combinations | 1 | 2010 | 2089 | 0.060 |
Why?
|
Cardiovascular Agents | 1 | 2010 | 849 | 0.060 |
Why?
|
Sex Factors | 3 | 2015 | 10632 | 0.050 |
Why?
|
Urology | 1 | 2008 | 384 | 0.050 |
Why?
|
Thoracic Surgery | 1 | 2010 | 727 | 0.050 |
Why?
|
Lung | 1 | 2022 | 10101 | 0.050 |
Why?
|
Demography | 2 | 2017 | 1641 | 0.050 |
Why?
|
Case-Control Studies | 3 | 2018 | 22290 | 0.050 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2008 | 1151 | 0.050 |
Why?
|
Government Programs | 1 | 2005 | 278 | 0.050 |
Why?
|
Glucose Tolerance Test | 1 | 2006 | 1183 | 0.050 |
Why?
|
Efficiency, Organizational | 1 | 2007 | 697 | 0.050 |
Why?
|
Health Care Sector | 1 | 2005 | 196 | 0.050 |
Why?
|
Professional Autonomy | 1 | 2004 | 172 | 0.050 |
Why?
|
Epidemiologic Methods | 1 | 2008 | 1328 | 0.050 |
Why?
|
Office Visits | 1 | 2007 | 595 | 0.050 |
Why?
|
Emergency Service, Hospital | 4 | 2021 | 7951 | 0.050 |
Why?
|
Anxiety | 2 | 2015 | 4672 | 0.050 |
Why?
|
Financial Management | 1 | 2004 | 161 | 0.050 |
Why?
|
Program Evaluation | 2 | 2023 | 2507 | 0.050 |
Why?
|
Heart Failure | 2 | 2017 | 11879 | 0.050 |
Why?
|
Anemia | 1 | 2012 | 1514 | 0.050 |
Why?
|
Hypnotics and Sedatives | 1 | 2010 | 1191 | 0.050 |
Why?
|
Health Status Indicators | 1 | 2007 | 969 | 0.050 |
Why?
|
Mental Health Services | 1 | 2013 | 1732 | 0.050 |
Why?
|
Exercise | 1 | 2018 | 5954 | 0.050 |
Why?
|
District of Columbia | 1 | 2002 | 159 | 0.050 |
Why?
|
Georgia | 1 | 2002 | 186 | 0.050 |
Why?
|
Prevalence | 5 | 2021 | 15869 | 0.050 |
Why?
|
Women | 1 | 1983 | 225 | 0.050 |
Why?
|
Adult Children | 1 | 2022 | 104 | 0.050 |
Why?
|
Baltimore | 1 | 2002 | 233 | 0.050 |
Why?
|
Axilla | 1 | 2003 | 623 | 0.050 |
Why?
|
Age Distribution | 2 | 2018 | 2873 | 0.050 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 1515 | 0.040 |
Why?
|
Florida | 1 | 2002 | 417 | 0.040 |
Why?
|
Telemedicine | 2 | 2018 | 3109 | 0.040 |
Why?
|
Boston | 2 | 2011 | 9374 | 0.040 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 2271 | 0.040 |
Why?
|
Benchmarking | 1 | 2007 | 1057 | 0.040 |
Why?
|
Hematologic Neoplasms | 1 | 2012 | 1907 | 0.040 |
Why?
|
Southeastern United States | 1 | 2020 | 93 | 0.040 |
Why?
|
Contraceptive Agents | 1 | 2021 | 148 | 0.040 |
Why?
|
Cognition | 2 | 2017 | 7073 | 0.040 |
Why?
|
Spouses | 1 | 2022 | 286 | 0.040 |
Why?
|
Health Services Administration | 1 | 2000 | 63 | 0.040 |
Why?
|
Self Care | 1 | 2004 | 799 | 0.040 |
Why?
|
Matched-Pair Analysis | 1 | 1999 | 285 | 0.040 |
Why?
|
Drug Therapy, Combination | 1 | 2009 | 6316 | 0.040 |
Why?
|
Morbidity | 2 | 2018 | 1755 | 0.040 |
Why?
|
Suicide | 1 | 2010 | 1606 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 3 | 2022 | 36741 | 0.040 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2018 | 67 | 0.040 |
Why?
|
England | 1 | 1999 | 533 | 0.040 |
Why?
|
Physicians' Offices | 1 | 2018 | 60 | 0.040 |
Why?
|
Cholesterol, LDL | 1 | 2007 | 2403 | 0.040 |
Why?
|
Imidazolidines | 1 | 2017 | 38 | 0.040 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2023 | 1339 | 0.040 |
Why?
|
Societies, Medical | 1 | 2010 | 3968 | 0.040 |
Why?
|
Decision Support Techniques | 1 | 2007 | 2008 | 0.040 |
Why?
|
Education, Medical, Graduate | 1 | 2010 | 2420 | 0.040 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2005 | 934 | 0.040 |
Why?
|
Genes, Tumor Suppressor | 1 | 2022 | 1062 | 0.040 |
Why?
|
Tosyl Compounds | 1 | 2017 | 115 | 0.040 |
Why?
|
Flutamide | 1 | 2017 | 95 | 0.040 |
Why?
|
Selection Bias | 1 | 1999 | 360 | 0.040 |
Why?
|
Occult Blood | 1 | 2018 | 199 | 0.030 |
Why?
|
Critical Care | 3 | 2016 | 2715 | 0.030 |
Why?
|
Tooth Loss | 1 | 1998 | 200 | 0.030 |
Why?
|
Community Health Centers | 1 | 2020 | 469 | 0.030 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2018 | 392 | 0.030 |
Why?
|
Prostate | 2 | 2018 | 1765 | 0.030 |
Why?
|
Models, Statistical | 1 | 2010 | 5107 | 0.030 |
Why?
|
Eukaryotic Initiation Factor-3 | 1 | 2015 | 47 | 0.030 |
Why?
|
Bipolar Disorder | 1 | 2012 | 5130 | 0.030 |
Why?
|
Injections, Intraperitoneal | 1 | 2015 | 411 | 0.030 |
Why?
|
Radiography | 1 | 2006 | 6986 | 0.030 |
Why?
|
Anilides | 1 | 2017 | 413 | 0.030 |
Why?
|
Stress, Psychological | 1 | 2010 | 4530 | 0.030 |
Why?
|
Latin America | 1 | 2015 | 416 | 0.030 |
Why?
|
Gynecomastia | 1 | 2014 | 88 | 0.030 |
Why?
|
Antipsychotic Agents | 1 | 2007 | 3081 | 0.030 |
Why?
|
Schizophrenia | 1 | 2012 | 6983 | 0.030 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2018 | 465 | 0.030 |
Why?
|
Michigan | 1 | 2014 | 330 | 0.030 |
Why?
|
Documentation | 1 | 2020 | 917 | 0.030 |
Why?
|
Disease Progression | 3 | 2015 | 13668 | 0.030 |
Why?
|
Cesarean Section | 1 | 2022 | 1425 | 0.030 |
Why?
|
Insulin Resistance | 1 | 2006 | 3986 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2008 | 8648 | 0.030 |
Why?
|
Blood Pressure | 1 | 2007 | 8543 | 0.020 |
Why?
|
Bereavement | 1 | 2016 | 310 | 0.020 |
Why?
|
Hot Flashes | 1 | 2014 | 330 | 0.020 |
Why?
|
Sweating | 1 | 2012 | 155 | 0.020 |
Why?
|
Watchful Waiting | 1 | 2015 | 492 | 0.020 |
Why?
|
Contraceptives, Oral | 1 | 2013 | 560 | 0.020 |
Why?
|
Blood Cell Count | 1 | 2012 | 406 | 0.020 |
Why?
|
Pregnancy Outcome | 1 | 2022 | 2972 | 0.020 |
Why?
|
Chronic Disease | 1 | 2005 | 9384 | 0.020 |
Why?
|
Sampling Studies | 1 | 2012 | 615 | 0.020 |
Why?
|
Bone Diseases, Metabolic | 1 | 2014 | 411 | 0.020 |
Why?
|
Tumor Burden | 1 | 2016 | 1906 | 0.020 |
Why?
|
Lymphatic Diseases | 1 | 2012 | 319 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2015 | 1737 | 0.020 |
Why?
|
American Cancer Society | 1 | 2010 | 69 | 0.020 |
Why?
|
Canada | 1 | 2015 | 2130 | 0.020 |
Why?
|
Adenocarcinoma | 2 | 2018 | 6395 | 0.020 |
Why?
|
Databases as Topic | 1 | 2012 | 472 | 0.020 |
Why?
|
Coronary Artery Disease | 1 | 2009 | 6568 | 0.020 |
Why?
|
Hospitals, Urban | 1 | 2012 | 497 | 0.020 |
Why?
|
Carcinoma, Small Cell | 1 | 2012 | 419 | 0.020 |
Why?
|
Poisson Distribution | 1 | 2011 | 506 | 0.020 |
Why?
|
Internship and Residency | 1 | 2010 | 5953 | 0.020 |
Why?
|
Markov Chains | 1 | 2013 | 979 | 0.020 |
Why?
|
Treatment Failure | 1 | 2015 | 2661 | 0.020 |
Why?
|
Comparative Effectiveness Research | 1 | 2014 | 714 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2015 | 2357 | 0.020 |
Why?
|
Organizational Culture | 1 | 2013 | 513 | 0.020 |
Why?
|
Probability | 1 | 2014 | 2479 | 0.020 |
Why?
|
Muscle Proteins | 1 | 2014 | 1165 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2016 | 4861 | 0.020 |
Why?
|
Deoxycytidine | 1 | 2013 | 887 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2020 | 2726 | 0.020 |
Why?
|
Treatment Refusal | 1 | 2011 | 433 | 0.020 |
Why?
|
Qualitative Research | 1 | 2019 | 3140 | 0.020 |
Why?
|
Hospital Administration | 1 | 2012 | 351 | 0.020 |
Why?
|
Fluorouracil | 1 | 2013 | 1652 | 0.020 |
Why?
|
Metabolic Diseases | 1 | 2014 | 684 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2018 | 5315 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2014 | 1397 | 0.020 |
Why?
|
Vaccination | 1 | 1999 | 3437 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2008 | 18065 | 0.020 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2010 | 794 | 0.020 |
Why?
|
Informed Consent | 1 | 2012 | 1010 | 0.020 |
Why?
|
Urologic Surgical Procedures | 1 | 2008 | 281 | 0.020 |
Why?
|
Alzheimer Disease | 1 | 2007 | 8759 | 0.020 |
Why?
|
American Heart Association | 1 | 2010 | 1050 | 0.010 |
Why?
|
Europe | 1 | 2011 | 3436 | 0.010 |
Why?
|
Body Composition | 1 | 2014 | 2462 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2016 | 10763 | 0.010 |
Why?
|
Hospital Mortality | 2 | 2016 | 5349 | 0.010 |
Why?
|
Thrombolytic Therapy | 1 | 1992 | 2055 | 0.010 |
Why?
|
ROC Curve | 1 | 2011 | 3628 | 0.010 |
Why?
|
Employee Performance Appraisal | 1 | 1983 | 86 | 0.010 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2018 | 4058 | 0.010 |
Why?
|
Mastectomy, Modified Radical | 1 | 2002 | 62 | 0.010 |
Why?
|
Endoscopy | 1 | 2012 | 1854 | 0.010 |
Why?
|
Myelodysplastic Syndromes | 1 | 2012 | 1399 | 0.010 |
Why?
|
Retirement | 1 | 1983 | 198 | 0.010 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2012 | 1437 | 0.010 |
Why?
|
Child | 2 | 2023 | 80917 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2018 | 4887 | 0.010 |
Why?
|
Weight Loss | 1 | 2012 | 2721 | 0.010 |
Why?
|
Neuropsychological Tests | 1 | 2013 | 7140 | 0.010 |
Why?
|
Adaptation, Psychological | 1 | 2010 | 2663 | 0.010 |
Why?
|
Alendronate | 1 | 1998 | 174 | 0.010 |
Why?
|
Primary Prevention | 1 | 2004 | 1188 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2012 | 13013 | 0.010 |
Why?
|
Cholesterol | 1 | 2004 | 2914 | 0.010 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 1998 | 399 | 0.010 |
Why?
|
Infant | 1 | 2013 | 36535 | 0.010 |
Why?
|
Child, Preschool | 1 | 2013 | 42669 | 0.010 |
Why?
|
Double-Blind Method | 1 | 1998 | 12466 | 0.000 |
Why?
|